CytoNiche
华龛生物
CytoNiche (华龛生物) is a Beijing-based biotech company that develops 3D cell manufacturing platforms for cell therapy applications, positioning itself as a provider of end-to-end "smart manufacturing" solutions for scalable three-dimensional cell production . The company raised nearly RMB 300 million in a Series B round in early 2022, co-led by Gaorong Ventures and CICC Capital funds, with Sinovac and China National Biotec Group among the follow-on investors . In 2025, it closed a Series B+ round of several hundred million RMB that brought in new backers including the Beijing Medical and Health Industry Investment Fund and Beijing New Materials Industry Investment Fund, among others . Its product lineup includes the 3D FloTrix® microSPIN 6-channel mini bioreactor, released in late 2022 for cell drug R&D .
AI-generated — may contain errors, please verify.
Coverage
3D Cell Manufacturing Platform Huaxin Biotech Closes Series B+ Round to Accelerate Cell Therapy Commercialization for Global Clients
Ushering in the 2.0 era of cell-based industrialization.
高榕创投·Consumer/Medical Companies Launch New Products, Advanced Tech Market Share and Capacity Advance Further | Rongbao · November
Explore industry demand, and build solid R&D capabilities.
高榕创投·Global SaaS, New Brands, and Biopharma Companies Close New Funding Rounds | Rongbao · February
The vitality of spring.
高榕创投·Viva Biotech Completes Nearly RMB 300 Million Series B Funding Round to Accelerate Industrialization of 3D Cell "Smart Manufacturing"
Gaorong Ventures co-led the round.
高榕创投·
